Unlock instant, AI-driven research and patent intelligence for your innovation.

Intein proteins and uses thereof

An internal protein and protein technology, applied in the fields of constructs, vectors, related host cells and pharmaceutical compositions, can solve the problems of low transgene expression efficiency and so on

Pending Publication Date: 2021-09-03
特莱索恩基金会
View PDF22 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the efficiency of transgene expression achieved with dual or triple AAV vectors is lower than that achieved with single AAV vectors (6, 13, 14)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Intein proteins and uses thereof
  • Intein proteins and uses thereof
  • Intein proteins and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0904] Example 1: AAV-EGFP protein in the full length protein reconstituted in vitro

[0905] The present inventors tested the efficiency of the retina-mediated protein trans-splicing; formation of two AAV vectors, each vector encoding point are candidiasis [ figure 1 N-terminus or C-terminus and C-terminus of the N-terminal half of the halves of Npu A] of the split-type DnaE protein fused to EGFP reporter protein. EGFP protein amino acids in the cleavage (a.a.) at C71. Each AAV vectors comprise appropriate regulatory elements (i.e., promoter and bovine growth hormone polyadenylation signal (bGHpA) and triple flag tag (3xflag), to allow detection of the two halves and the reconstructed full-length EGFP protein ( figure 1 A).

[0906] Generated using the E protein plasmid transfected human embryonic kidney 293 (HEK293) cells and evaluated single N and C-terminal halves of the full-length EGFP protein and AAV-EGFP Dna. Detected in the cell pellet and the AAV-protein EGFP, rather tha...

Embodiment 2

[0911] AAV-EGFP more effective than double the protein of AAV vectors in vitro: Example 2

[0912] To confirm the protein from the reconstructed EGFP protein AAV vectors, so that HEK293 cells infected with AAV2 / 2-CMV-EGFP or the DnaE protein comprising a single and dual expression cassette same AAV vectors. Multiplicity of infection (m.o.i) 5x10 ^ 4 genome copies (GC) / vector per cell, which means assuming a double dose of between similar proteins or recombinant DNA vector, three experienced complete system. In order to accurately quantify the amount of EGFP, were harvested at 72 hours post-infection cell lysates. By ELISA and WB assay (ELISA) to evaluate both the EGFP expression: using the AAV protein EGFP expression vector was expressed in about half of AAV obtained using a single (single AAV = 0.735 ± 0.2ng EGFP / μg total lysate, n = 5 separate experiments; the AAV protein = 0.403 ± 0.04ng EGFP / μg total lysate, n = 5 separate experiments) and dual expression than AAV vect...

Embodiment 3

[0913] Example 3: the subretinal AAV-EGFP fusion expression vectors results in both mice and pigs administered retina effectively reconstructed full-length protein.

[0914] To the AAV-mediated trans-splicing whether the reconstructed full-length protein expressed in the retina, for the injection of 4-week-old C57BL / 6J mice retinal AAV2 / 8-CMV-EGFP Dna E protein carrier (each carrier Study dose / eye: 5.8x10 ^ 9GC). Harvest eye and analyzed by microscopy analysis after 1 month. In all ocular retinal pigment epithelium, most importantly, the detection of EGFP fluorescence in photoreceptors ( figure 1 D). To transgene expression and transgene expression from AAV single and double inner AAV proteins are compared in a photoreceptor, in the injection of G protein coupled receptor photoreceptor-specific human retina at 4-week-old mice C57BL / 6J kinase 1 (GRK1) under the control of a promoter AAV2 / 8 vector encoding EGFP (each carrier / eye dose: 5x10 ^ 9GC). 1 month after injection...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to constructs, vectors, relative host cells and pharmaceutical compositions which allow an effective gene therapy, in particular of genes larger than 5Kb.

Description

Technical field [0001] The present invention relates to a construct body, a carrier, associated host cell, and a pharmaceutical composition that allows effective gene therapy, particularly an effective gene therapy caused by a disease caused by a mutation of a gene of a gene encoding a sequence (CDS). Background technique [0002] Genetic therapy with glandular virus (AAV) vector is safe and effective for people. AAV-based gene therapy products have been approved for genetic metabolism and blindness in the United States and Europe, and the clinical trial of AV-based gene therapy methods based on diseases in different treatments are also increasing. The disease range is an ophthalmology to a blood disease to myoston and metabolic disease. [0003] However, the AAV carrier cargo capacity prevents the development of AV-based therapy caused by the disease caused by the coding sequence (CDS) greater than 5 kB (also known as the large gene herein). [0004] Genetic diseases caused by l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/86
CPCC12N15/86C12N2750/14141A61K48/00A61P27/02C12N2750/14143C12N2320/33A61P7/04
Inventor A.奥里克奇奥I.特拉帕尼P.托纳贝内
Owner 特莱索恩基金会